Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment

Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis...

Descripción completa

Detalles Bibliográficos
Autores principales: Volkova, Maria, Russell, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322439/
https://www.ncbi.nlm.nih.gov/pubmed/22758622
http://dx.doi.org/10.2174/157340311799960645
_version_ 1782229064823603200
author Volkova, Maria
Russell, Raymond
author_facet Volkova, Maria
Russell, Raymond
author_sort Volkova, Maria
collection PubMed
description Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition.
format Online
Article
Text
id pubmed-3322439
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-33224392012-11-01 Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment Volkova, Maria Russell, Raymond Curr Cardiol Rev Article Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition. Bentham Science Publishers 2011-11 2011-11 /pmc/articles/PMC3322439/ /pubmed/22758622 http://dx.doi.org/10.2174/157340311799960645 Text en © 2011 Bentham Science Publishers http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Volkova, Maria
Russell, Raymond
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
title Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
title_full Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
title_fullStr Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
title_full_unstemmed Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
title_short Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
title_sort anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322439/
https://www.ncbi.nlm.nih.gov/pubmed/22758622
http://dx.doi.org/10.2174/157340311799960645
work_keys_str_mv AT volkovamaria anthracyclinecardiotoxicityprevalencepathogenesisandtreatment
AT russellraymond anthracyclinecardiotoxicityprevalencepathogenesisandtreatment

Ejemplares similares